Pharma company Lupin gets USFDA go-ahead to market generic anti-bacterial drug
Drug maker Lupin on Wednesday said it has received a US health regulator's nod to market generic version of Flagyl tablets, a drug used to treat bacterial infections, in the American market.
Drug maker Lupin on Wednesday said it has received a US health regulator's nod to market generic version of Flagyl tablets, a drug used to treat bacterial infections, in the American market.
The company has received final approval from the US Food and Drug Administration (US FDA) to market metronidazole tablets in strengths of 250 mg and 500 mg, Lupin said in a statement.
The Mumbai-based company's product is a generic version of G D Searle LLC's Flagyl tablets which are indicated in the treatment of a wide variety of bacterial infections.
As per IMS MAT sales June data, Flagyl tablets had sales of USD 44.1 million in the US market.
Lupin shares today closed 1.39 per cent up at Rs 995 per scrip on BSE